SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Samsung Q2 Profit Surges on AI Memory Chip Demand, Forecasts Strong Second Half 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
EDEN PRAIRIE, Minn., April 26, 2018 -- CHF Solutions, Inc. (Nasdaq:CHFS) announces today that new comparative data between the company’s Aquadex FlexFlow system and pharmaceutical therapy will be presented in a poster session at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) conference.
The poster, titled “Ultrafiltration vs. Diuretics for the Treatment of Fluid Overload in Heart Failure Patients: A Hospital Cost Analysis,” will be presented on Wednesday, May 23, 2018 at the Baltimore Convention Center, Baltimore, Md.
“We have long established the viability of ultrafiltration therapy through both robust clinical evidence and customer experience,” said John Erb, chairman and chief executive officer of CHF Solutions. "We are pleased to be presenting these data at the ISPOR conference, which will provide additional evidence for physicians to consider when choosing a therapy for fluid overloaded heart failure patients.”
About CHF Solutions
CHF Solutions, Inc. (NASDAQ:CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow system for Aquapheresis® therapy. The Aquadex FlexFlow system is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company's mission is to predict, measure, and control patient fluid balance through science, collaboration, and innovative medical technology. CHF Solutions is a Delaware corporation headquartered in Minneapolis, Minnesota with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the NASDAQ Capital Market since February 2012.
CONTACTS:
INVESTORS:
Claudia Napal Drayton
Chief Financial Officer
CHF Solutions, Inc.
952-345-4205
[email protected]
-or-
Bret Shapiro
Managing Partner
CORE IR
516-222-2560
[email protected]
www.coreir.com
MEDIA
Jules Abraham
JQA Partners, Inc.
917-885-7378
[email protected]
